BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31253840)

  • 21. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Evaluation of
    Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
    Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
    Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
    Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
    J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
    Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.
    Hofstrom C; Orlova A; Altai M; Wangsell F; Graslund T; Tolmachev V
    J Med Chem; 2011 Jun; 54(11):3817-26. PubMed ID: 21524142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
    Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Molavipordanjani S; Khodashenas S; Abedi SM; Moghadam MF; Mardanshahi A; Hosseinimehr SJ
    Eur J Pharm Sci; 2020 May; 148():105312. PubMed ID: 32198014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
    Orlova A; Hofström C; Strand J; Varasteh Z; Sandstrom M; Andersson K; Tolmachev V; Gräslund T
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):439-49. PubMed ID: 23179942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [
    Bragina O; Chernov V; Schulga A; Konovalova E; Hober S; Deyev S; Sörensen J; Tolmachev V
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
    Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
    Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
    Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
    Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.
    Rosik D; Thibblin A; Antoni G; Honarvar H; Strand J; Selvaraju RK; Altai M; Orlova A; Eriksson Karlström A; Tolmachev V
    Bioconjug Chem; 2014 Jan; 25(1):82-92. PubMed ID: 24344772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
    Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.
    Zhang JM; Zhao XM; Wang SJ; Ren XC; Wang N; Han JY; Jia LZ
    Br J Radiol; 2014 Jan; 87(1033):20130484. PubMed ID: 24273251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.